CA2179282A1 - Produits pharmaceutiques - Google Patents

Produits pharmaceutiques

Info

Publication number
CA2179282A1
CA2179282A1 CA002179282A CA2179282A CA2179282A1 CA 2179282 A1 CA2179282 A1 CA 2179282A1 CA 002179282 A CA002179282 A CA 002179282A CA 2179282 A CA2179282 A CA 2179282A CA 2179282 A1 CA2179282 A1 CA 2179282A1
Authority
CA
Canada
Prior art keywords
treatment
composition according
compound
formula
zap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002179282A
Other languages
English (en)
Inventor
Ronald James Boon
David Ronald John Griffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2179282A1 publication Critical patent/CA2179282A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Une méthode de traitement (y compris de prophylaxie) des douleurs associées au zona chez les mammifères, notamment chez l'homme, consiste à administrer au mammifère nécessitant un tel traitement une quantité efficace d'un composé de formule (A) ou d'un bioprécurseur, ou d'un sel pharmaceutiquement acceptable, d'un ester de phosphate et/ou d'un dérivé acyle du composé ou du bioprécurseur. On utilise ce composé de la formule (A) ou un bioprécurseur, ou un sel pharmacologiquement acceptable, un ester de phosphate et/ou un dérivé acyle du composé ou du bioprécurseur, dans la fabrication d'un médicament destiné à être utilisé dans le traitement (y compris la prophylaxie) des douleurs associées au zona.
CA002179282A 1993-12-22 1994-12-14 Produits pharmaceutiques Abandoned CA2179282A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9326177.4 1993-12-22
GB939326177A GB9326177D0 (en) 1993-12-22 1993-12-22 Pharmaceuticals
PCT/EP1994/004163 WO1995017190A1 (fr) 1993-12-22 1994-12-14 Produits pharmaceutiques

Publications (1)

Publication Number Publication Date
CA2179282A1 true CA2179282A1 (fr) 1995-06-29

Family

ID=10747023

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002179282A Abandoned CA2179282A1 (fr) 1993-12-22 1994-12-14 Produits pharmaceutiques

Country Status (8)

Country Link
EP (1) EP0735878A1 (fr)
JP (1) JPH09506883A (fr)
CN (1) CN1084622C (fr)
AU (1) AU697290B2 (fr)
CA (1) CA2179282A1 (fr)
GB (1) GB9326177D0 (fr)
WO (1) WO1995017190A1 (fr)
ZA (1) ZA9410113B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980028023A (ko) * 1996-10-19 1998-07-15 김준웅 Ο-아실-ο-아미노산 9-(4-하이드록시-3-하이드록시메틸부트-1-일구아닌 에스테르 유도체

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485225D1 (de) * 1983-08-18 1991-12-05 Beecham Group Plc Antivirale guanin-derivate.
EP0182024B1 (fr) * 1984-09-20 1991-04-03 Beecham Group Plc Dérivés de purine et leur utilisation pharmaceutique
DE3671227D1 (de) * 1985-07-27 1990-06-21 Beecham Group Plc 9-substituierte guaninmonohydrate.
GB8628826D0 (en) * 1986-12-02 1987-01-07 Beecham Group Plc Pharmaceutical products
GB8904855D0 (en) * 1989-03-03 1989-04-12 Beecham Group Plc Pharmaceutical treatment
GB8917959D0 (en) * 1989-08-05 1989-09-20 Beecham Group Plc Pharmaceutical formulation
GB9001886D0 (en) * 1990-01-26 1990-03-28 Beecham Group Plc Pharmaceutical formulation
GB9015051D0 (en) * 1990-07-07 1990-08-29 Beecham Group Plc Pharmaceutical treatment
GB9114939D0 (en) * 1991-07-11 1991-08-28 Smithkline Beecham Plc Pharmaceutical formulation

Also Published As

Publication number Publication date
JPH09506883A (ja) 1997-07-08
CN1084622C (zh) 2002-05-15
CN1142769A (zh) 1997-02-12
EP0735878A1 (fr) 1996-10-09
ZA9410113B (en) 1995-08-25
GB9326177D0 (en) 1994-02-23
WO1995017190A1 (fr) 1995-06-29
AU1383495A (en) 1995-07-10
AU697290B2 (en) 1998-10-01

Similar Documents

Publication Publication Date Title
KR101838764B1 (ko) (ｅ)-4-카복시스티릴-4-클로로벤질설폰의 개선된 안정한 수성 제형
JP2008088189A (ja) 潜伏ヘルペスウイルス感染の治療および予防のためのアミノプリン抗ウイルス剤の使用
EP0388049B1 (fr) Dérivés de penciclovir pour le traitement d'infections de l'Hépatite-B
JPH0320222A (ja) 脳内虚血症治療剤
CA2179282A1 (fr) Produits pharmaceutiques
US4617311A (en) Antiasthmatic method
AU696833B2 (en) Use of 2-amino purine derivatives for the treatment and prophylaxis of human herpes virus 7 infection
AU7788494A (en) Use of penciclorin for the treatment of post-therapeutic neuralgia
EP0830862A1 (fr) Medicaments anti-vih
EP0476391A2 (fr) Composition anti-SIDA contenant cépharanthine comme agent thérapeutique
EP0728001B1 (fr) Utilisation de derives de 2-amino purine utilises dans le traitement et la prophylaxie des infections dues a l'herpesvirus 6 chez l'homme
AU7860394A (en) Use of peniclorin for the treatment of posttherapeutic neuralgia
JPH11130672A (ja) 脂質過酸化抑制剤
JPH06227982A (ja) 抗ウイルス剤
JPH11501625A (ja) ヒト・ヘルペスウイルス−８の治療に対するペンシクロビルの使用
JPH0395116A (ja) 逆転写酵素阻害組成物
GB2201343A (en) Lowering blood uric acid levels
JPH04139128A (ja) 抗ウィルス組成物
MXPA97004336A (en) Use of antiviral agents for the treatment and prophylaxis of latent infections of herpesvi
JPS63295579A (ja) 骨粗鬆症治療剤
JPH04139130A (ja) 抗ウィルス組成物
WO1999022730A1 (fr) Utilisation de (+)-6-carboxamido-3-methylamino-1,2,3,4-tetrahydrocarbazole pour le traitement de l'hyperalgie
JPH01168614A (ja) 抗腫瘍剤
JPH10510278A (ja) 潜伏ヘルペスウイルス感染の治療および予防のためのアミノプリン抗ウイルス剤の使用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead